Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cue Biopharma Inc (NQ: CUE )

3.570 +0.030 (+0.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 281,533
Open 3.600
Bid (Size) 3.380 (6)
Ask (Size) 3.790 (3)
Prev. Close 3.540
Today's Range 3.440 - 3.600
52wk Range 2.180 - 6.290
Shares Outstanding 43,168,468
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cue Biopharma Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via Globe NewsWire

Performance

YTD
+34.21%
+34.21%
1 Month
+25.70%
+25.70%
3 Month
+25.26%
+25.26%
6 Month
+60.09%
+60.09%
1 Year
-26.84%
-26.84%

More News

Read More
Earnings Scheduled For March 21, 2023
Via Benzinga
Cue Biopharma's Earnings Outlook
Via Benzinga
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via Globe NewsWire
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
From Cue Biopharma, Inc.
Via Globe NewsWire
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
From Cue Biopharma, Inc.
Via Globe NewsWire
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
From Cue Biopharma, Inc.
Via Globe NewsWire
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
From Cue Biopharma, Inc.
Via Globe NewsWire
Cue Biopharma to Present at Two February 2023 Scientific Conferences
From Cue Biopharma, Inc.
Via Globe NewsWire
Cue Biopharma Announces Chief Medical Officer Transition
From Cue Biopharma, Inc.
Via Globe NewsWire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
From Cue Biopharma, Inc.
Via Globe NewsWire
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)
Via ACCESSWIRE
Cue Biopharma Reports Third Quarter 2022 Financial Results
From Cue Biopharma, Inc.
Via Globe NewsWire
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
From Cue Biopharma, Inc.
Via Globe NewsWire
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Cue Biopharma, Inc.
Via Globe NewsWire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
From Cue Biopharma, Inc.
Via Globe NewsWire
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Why Soluna Holdings Shares Are Trading Sharply Lower; Here Are 38 Stocks Moving Premarket
Via Benzinga
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Cue Biopharma, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
From Cue Biopharma, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.